ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

@article{Casaluce2012ALKIA,
  title={ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC},
  author={Francesca Casaluce and Assunta Sgambato and Paolo Maione and Antonio Rossi and Carmine Ferrara and Alba Napolitano and Giovanni Palazzolo and Fortunato Ciardiello and Cesare Gridelli},
  journal={Targeted Oncology},
  year={2012},
  volume={8},
  pages={55-67}
}
The anaplastic lymphoma kinase (ALK) fusion gene is a key oncogenic driver in a subset of patients with advanced non-small cell lung cancer (NSCLC). Oncogenic fusion genes, including echinoderm microtubule-associated protein-like 4 (EML4) and ALK, have been detected in approximately 2–7 % of NSCLC patients. Fluorescence in situ hybridization (FISH) is the recommended method for detecting ALK gene rearrangement. EML4–ALK fusion genes define a molecular subset of NSCLC with distinct clinical… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 91 references

Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC)

E Felip, E Carcenery, F Barlesi
ESMO • 2012
View 10 Excerpts
Highly Influenced

A phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portion

M Nishio, K Kiura, K Nakagawa
ESMO • 2012
View 2 Excerpts

Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients

RC Doebele, DL Aisner, AT Le
J Clin Oncol • 2012
View 1 Excerpt

Clinical activity of crizotinib in patients with advanced non-small cell lung cancer harboring ROS1 gene rearrangement

SI Ou, DR Camidge, JA Engelman
ESMO • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…